The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy : Implications for Complement-Targeted Therapies
Querol, Luis (Institut d'Investigació Biomèdica Sant Pau)
Hartung, Hans-Peter (Palacky University Olomouc)
Lewis, Richard A. (Cedars Sinai Medical Center)
van Doorn, Pieter A. (University Medical Center)
Hammond, Timothy R. (Sanofi)
Atassi, Nazem (Sanofi)
Alonso-Alonso, Miguel (Sanofi)
Dalakas, Marinos C. (Neuroimmunology National and Kapodistrian University of Athens Medical School)
Universitat Autònoma de Barcelona

Date:	2022
Abstract:	Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common, heterogeneous, immune-mediated neuropathy, characterized by predominant demyelination of motor and sensory nerves. CIDP follows a relapsing-remitting or a progressive course and causes substantial disability. The pathogenesis of CIDP involves a complex interplay of multiple aberrant immune responses, creating a pro-inflammatory environment, subsequently inflicting damage on the myelin sheath. Though the exact triggers are unclear, diverse immune mechanisms encompassing cellular and humoral pathways are implicated. The complement system appears to play a role in promoting macrophage-mediated demyelination. Complement deposition in sural nerve biopsies, as well as signs of increased complement activation in serum and CSF of patients with CIDP, suggest complement involvement in CIDP pathogenesis. Here, we present a comprehensive overview of the preclinical and clinical evidence supporting the potential role of the complement system in CIDP. This understanding furnishes a strong rationale for targeting the complement system to develop new therapies that could serve the unmet needs of patients affected by CIDP, particularly in those refractory to standard therapies.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	CIDP ; Complement inhibition ; Complement system ; Demyelination ; Pathogenesis ; Peripheral neuropathy
Published in:	Neurotherapeutics, Vol. 19 Núm. 3 (april 2022) , p. 864-873, ISSN 1878-7479

DOI: 10.1007/s13311-022-01221-y
PMID: 35378684

10 p, 922.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles